Creative Planning
NVET

Creative Planning’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Creative Planning’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,000
Closed -$4K – 5088
2016
Q4 		$4K Buy
+1,000
New +$4.13K ﹤0.01% 4110

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
LLC
Latimer Light Capital New York $432M AUM 25.5% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Creative Planning's NVET Position: Q1 2017 in Review

Creative Planning sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q1 2017, closing a stake of 1,000 shares — an estimated $4K sold.

Creative Planning first reported a position in NVET in Q4 2016 and held it in 1 quarter. The position peaked at $4K in Q4 2016. 13 funds tracked by Wall St. Rank hold NVET as of Q1 2017.

  • Creative Planning reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • Creative Planning sold 1,000 Nexvet Biopharma plc Ordinary Shares shares in Q1 2017, an estimated $4K.
  • Creative Planning first reported a position in Nexvet Biopharma plc Ordinary Shares in Q4 2016 and held it in 1 quarter.
  • Creative Planning's Nexvet Biopharma plc Ordinary Shares position peaked at $4K in Q4 2016.
  • 13 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q1 2017.

Based on Creative Planning's 13F filing for Q1 2017, filed 7 Apr 2017.